CollPlant Reports Successful Bio-Printing Of 200cc Breast Implants And Additional Pre-Clinical Data

6/6/24 7:16:47 AM ET

$CLGN

Industrial Specialties

Health Care

Get the next $CLGN alert in real time by email

Bio-printing technology now enables fabrication of 200cc implant size and above to address future commercial demand
Interim pre-clinical data shows tissue growth including regeneration of maturing connective tissue as well as neovascularization, synchronized with progressive implant degradation
No adverse tissue reaction was observed
Large-animal studies with commercial-size implants are currently underway with results expected in Q4 2024 and Q1 2025

Get the next $CLGN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CLGN

Date	Price Target	Rating	Analyst
2/17/2023	$22.75	Buy	Alliance Global Partners

More analyst ratings

$CLGN
Press Releases

Fastest customizable press release news feed in the world

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- Conference call to be held on Wednesday, November 27, 2024 at 10:00 a.m. U.S. EST - REHOVOT, Israel, Nov. 12, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2024 on Wednesday, November 27, 2024, before the opening of the U.S. financial markets. The Company will then host a conference call and webcast to discuss its financial results and corporate updates on November 27th at 10:00 a.m. Eastern Standard Time. Confere
11/12/24 7:00:00 AM ET
$CLGN
Industrial Specialties
Health Care
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
- Recently initiated a pre-clinical trial with CollPlant's rhCollagen-based regenerative breast implants, printed with Stratasys' Origin® 3D printer that are 200cc in volume - Breast implants could address a $3.0 billion market opportunity - Cash and cash equivalents balance as of June 30, 2024 was $18.9 million - Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, Aug. 20, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter
8/20/24 7:00:00 AM ET
$CLGN
$SSYS
Industrial Specialties
Health Care
Computer peripheral equipment
Technology
CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants
3D Printed Breast implants consisting of 200cc in volume of CollPlant's rhCollagen-based bioinks produced on a Stratasys' Origin® printer to be tested Technology innovation addresses a $3.0 billion market opportunity Study to focus on ability of implants to grow natural breast tissue and completely degrade over time In a significant step in the advancement of regenerative medicine, CollPlant Biotechnologies (NASDAQ:CLGN) and Stratasys Ltd. (NASDAQ:SSYS) today announced the initiation of a pre-clinical study with 200cc commercial-sized regenerative implants printed on a Stratasys Origin® 3D printer. This press release features multimedia. View the full release here: https://www.busine
8/19/24 8:30:00 AM ET
$CLGN
$SSYS
Industrial Specialties
Health Care
Computer peripheral equipment
Technology

$CLGN
Financials

Live finance-specific insights

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- Conference call to be held on Wednesday, November 27, 2024 at 10:00 a.m. U.S. EST - REHOVOT, Israel, Nov. 12, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2024 on Wednesday, November 27, 2024, before the opening of the U.S. financial markets. The Company will then host a conference call and webcast to discuss its financial results and corporate updates on November 27th at 10:00 a.m. Eastern Standard Time. Confere
11/12/24 7:00:00 AM ET
$CLGN
Industrial Specialties
Health Care
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
- Recently initiated a pre-clinical trial with CollPlant's rhCollagen-based regenerative breast implants, printed with Stratasys' Origin® 3D printer that are 200cc in volume - Breast implants could address a $3.0 billion market opportunity - Cash and cash equivalents balance as of June 30, 2024 was $18.9 million - Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, Aug. 20, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter
8/20/24 7:00:00 AM ET
$CLGN
$SSYS
Industrial Specialties
Health Care
Computer peripheral equipment
Technology
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 SECOND QUARTER FINANCIAL STATEMENTS AND CONFERENCE CALL INFORMATION
Conference call to be held on Tuesday, August 20, 2024, at 10:00 a.m. U.S. EDT REHOVOT, Israel, Aug. 6, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial statements for the second quarter of 2024 on Tuesday, August 20, 2024, before the opening of the U.S. financial markets. The Company will then host a conference call and webcast to discuss its financial statements and corporate updates on August 20 at 10:00 a.m. Eastern Daylight Time. Conference ca
8/6/24 7:00:00 AM ET
$CLGN
Industrial Specialties
Health Care

$CLGN
Leadership Updates

Live Leadership Updates

Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman. Dr. Pomerantz is
5/23/22 8:00:00 AM ET
$CFRX
$CLGN
$ENLV
$INDP
Biotechnology: Pharmaceutical Preparations
Health Care
Industrial Specialties
RION Appoints Alisa Lask as Chief Commercial Officer
- Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform - Two active FDA registrations RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer. "Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises," said Dr. Atta Behfar, Founder of RION. "She has prov
1/14/22 9:00:00 AM ET
$CLGN
$NEPH
Industrial Specialties
Health Care
Medical/Dental Instruments
CollPlant Appoints Medical Aesthetics Veteran Alisa Lask to Board of Directors
REHOVOT, Israel, Aug. 19, 2021 /PRNewswire/ -- CollPlant (NASDAQ:CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced the appointment of Alisa Lask to its Board of Directors. Ms. Lask is based in the United States and has held leadership roles in medical aesthetics at both Galderma and Allergan. She will be the seventh independent member of the CollPlant Board. "Alisa brings a strong background in global strategy and marketing that will be very helpful to maximizing the v
8/19/21 8:00:00 AM ET
$CLGN
Industrial Specialties
Health Care

CollPlant Reports Successful Bio-Printing Of 200cc Breast Implants And Additional Pre-Clinical Data

Chat with this insight

Recent Analyst Ratings for
$CLGN

$CLGN
Press Releases

Fastest customizable press release news feed in the world

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants

$CLGN
Financials

Live finance-specific insights

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 SECOND QUARTER FINANCIAL STATEMENTS AND CONFERENCE CALL INFORMATION

$CLGN
Market Insights

Live Market Insights

CollPlant Reports Successful Bio-Printing Of 200cc Breast Implants And Additional Pre-Clinical Data

HC Wainwright & Co. Reiterates Buy on CollPlant Biotechnologies, Maintains $11 Price Target

CollPlant Biotechnologies Q1 Adj $(0.35), Inline, Sales $98.00K Miss $600.00K Estimate

$CLGN
SEC Filings

$CLGN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$CLGN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form 6-K filed by CollPlant Biotechnologies Ltd

SEC Form 6-K filed by CollPlant Biotechnologies Ltd

SEC Form 6-K filed by CollPlant Biotechnologies Ltd

Alliance Global Partners initiated coverage on CollPlant with a new price target

HC Wainwright & Co. reiterated coverage on CollPlant Biotechnologies with a new price target

SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

$CLGN
Leadership Updates

Live Leadership Updates

Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

RION Appoints Alisa Lask as Chief Commercial Officer

CollPlant Appoints Medical Aesthetics Veteran Alisa Lask to Board of Directors

CollPlant Reports Successful Bio-Printing Of 200cc Breast Implants And Additional Pre-Clinical Data

Chat with this insight

Recent Analyst Ratings for $CLGN

$CLGN Press Releases

Fastest customizable press release news feed in the world

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants

$CLGN Financials

Live finance-specific insights

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 SECOND QUARTER FINANCIAL STATEMENTS AND CONFERENCE CALL INFORMATION

$CLGN Market Insights

Live Market Insights

CollPlant Reports Successful Bio-Printing Of 200cc Breast Implants And Additional Pre-Clinical Data

HC Wainwright & Co. Reiterates Buy on CollPlant Biotechnologies, Maintains $11 Price Target

CollPlant Biotechnologies Q1 Adj $(0.35), Inline, Sales $98.00K Miss $600.00K Estimate

$CLGN SEC Filings

$CLGN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$CLGN Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form 6-K filed by CollPlant Biotechnologies Ltd

SEC Form 6-K filed by CollPlant Biotechnologies Ltd

SEC Form 6-K filed by CollPlant Biotechnologies Ltd

Alliance Global Partners initiated coverage on CollPlant with a new price target

HC Wainwright & Co. reiterated coverage on CollPlant Biotechnologies with a new price target

SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

$CLGN Leadership Updates

Live Leadership Updates

Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

RION Appoints Alisa Lask as Chief Commercial Officer

CollPlant Appoints Medical Aesthetics Veteran Alisa Lask to Board of Directors

Recent Analyst Ratings for
$CLGN

$CLGN
Press Releases

$CLGN
Financials

$CLGN
Market Insights

$CLGN
SEC Filings

$CLGN
Analyst Ratings

$CLGN
Large Ownership Changes

$CLGN
Leadership Updates